Feature|Videos|January 9, 2025
Capacity and Surge Response Leading Into a State of Readiness
Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.
Advertisement
Episodes in this series
Declining pandemic readiness is cause for concern; as such, the panelists highlight the importance of maintaining manufacturing capacity, a skilled workforce, and robust health infrastructure. Sustainable practices, including leveraging flu vaccine systems, are recommended for better future preparedness.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
